STREAMEX CORP. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
STREAMEX CORP. (STEX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$6.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-31
- STREAMEX CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$6.70M.
- STREAMEX CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$8.40M, a 208.54% decline from fiscal 2023.
- STREAMEX CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $7.74M.
- STREAMEX CORP. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$5.64M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | -$6.70M 10-K · filed 2026-03-31 |
| 2024-12-31 | -$8.40M 10-K · filed 2026-03-31 |
| 2023-12-31 | $7.74M 10-K · filed 2024-04-16 |
| 2022-12-31 | -$5.64M 10-K · filed 2023-03-31 |
| 2021-12-31 | -$6.47M 10-K · filed 2022-03-31 |
| 2020-12-31 | -$9.20M 10-K · filed 2021-03-15 |
| 2019-12-31 | -$6.30M 10-K · filed 2020-03-13 |
| 2018-12-31 | -$1.00M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B |